<DOC>
	<DOCNO>NCT01662063</DOCNO>
	<brief_summary>This open-label extension study evaluate long-term safety efficacy SC TCZ participant moderate severe RA complete 97-week WA22762 ( NCT01194414 ) 96-week NA25220 ( NCT01232569 ) core study SC intravenous ( IV ) TCZ . Participants receive TCZ 162 milligram ( mg ) SC every week ( QW ) every 2 week ( Q2W ) 96 week .</brief_summary>
	<brief_title>A Long-Term Extension Study WA22762 NA25220 Subcutaneous ( SC ) Tocilizumab ( TCZ ) Moderate Severe Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Completed 97week WA22762 ( NCT01194414 ) 96week NA25220 ( NCT01232569 ) core study SC IV TCZ , base Investigator 's judgment , may continue benefit TCZ treatment study investigate SC formulation Receiving treatment outpatient basis Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception define protocol Premature withdrawal WA22762 ( NCT01194414 ) NA25220 ( NCT01232569 ) core study reason History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Evidence serious uncontrolled concomitant disease disorder Known active current history recurrent bacterial , viral , fungal , mycobacterial , infection Any major episode infection require hospitalization treatment IV antibiotic within 4 week Screening oral antibiotic within 2 week Screening History currently active primary secondary immunodeficiency Oral corticosteroid great ( &gt; ) 10 mg per day prednisone equivalent , nonsteroidal antiinflammatory drug ( NSAIDs ) maximum recommend dose Intraarticular parenteral corticosteroid within 4 week prior Baseline Treatment investigational commercially available biologic diseasemodifying antirheumatic drug ( DMARD ) TCZ time completion core study WA22762 ( NCT01194414 ) NA25220 ( NCT01232569 ) enrollment longterm extension study Pregnant breastfeed woman History alcohol , drug , chemical abuse within 1 year prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>